These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24384547)

  • 21. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
    Nakamura T; Fujiwara N; Sato E; Ueda Y; Sugaya T; Koide H
    Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
    Mizuno M; Sada T; Kato M; Koike H
    Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J; Kanno Y; Suzuki H
    Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin Receptor Blocker-Related Sprue-like Enteropathy: Review of Food and Drug Administration Adverse Event Reporting System.
    Meader R; Papasotiriou S; Ahdi H; Dang H; Ehrenpreis ED
    Ann Pharmacother; 2024 May; 58(5):494-500. PubMed ID: 37559251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama T; Matsumoto S; Matsumoto K
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):206-13. PubMed ID: 20197015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
    Bichu P; Nistala R; Khan A; Sowers JR; Whaley-Connell A
    Vasc Health Risk Manag; 2009; 5(1):129-40. PubMed ID: 19436679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
    Matsuda H; Hayashi K; Homma K; Yoshioka K; Kanda T; Takamatsu I; Tatematsu S; Wakino S; Saruta T
    Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P; Fairley K; Packham D
    Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis.
    Ye H; Huo Z; Ye P; Xiao G; Zhang Z; Xie C; Kong Y
    PeerJ; 2020; 8():e8575. PubMed ID: 32201639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
    Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
    Yanagi M; Tamura K; Fujikawa T; Wakui H; Kanaoka T; Ohsawa M; Azushima K; Maeda A; Kobori H; Umemura S
    Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
    Li L; Zhou N; Gong H; Wu J; Lin L; Komuro I; Ge J; Zou Y
    Hypertens Res; 2010 Dec; 33(12):1289-97. PubMed ID: 20944638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease.
    Rysavá R; Tesar V; Merta M;
    Blood Press Monit; 2005 Aug; 10(4):207-13. PubMed ID: 16077267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
    Goyache-Goñi B; Aranda-Lara P; Reyes-Engels A; Frutos-Sanz MA; Hernández-Marrero D
    Nefrologia; 2013 Nov; 33(6):771-8. PubMed ID: 24241364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
    ARB Trialists Collaboration
    J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.